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Purpose
Castleman’s disease (CD) is an uncommon lymphoproli-
ferative disorder, eventually complicated with paraneo-
plastic pemphigus (PNP) and pulmonary involvement.
The association of Behçet and CD is very rare and the
outcome is worse when PNP is present.
Methods
We describe a 17 yo female patient with Behçet’s syn-
drome and CD. She was affected by a 4-month history of
severe oral and genital ulcers, bilateral uveitis and
abdominal pain. A CT scan of the abdomen showed the
presence of a retroperitoneal mass (9,4 x 9,0 x 7,4 cm).
On the basis of histological and immunohistological find-
ings, a diagnosis of CD, hyaline vascular type, was formu-
lated. There was no lymphadenopathy, fever or anemia.
One month later, oral ulcers turned into desquamative
plaques, Nikolsky sign was observed and an oral biopsy
diagnosed paraneoplastic pemphigus. Ca 125 and Ca 19-
9 levels were elevated. The patient developed an acute
pleuritic pain with dyspnea, image exams revealed pneu-
momediastinum, pneumothorax and subcutaneous
emphysema, and a bronchoscopy revealed a tracheal
lesion suggestive of pemphigus. No signs of infection
were present and pulses of methylprednisolone were pre-
scribed, with good initial response. After the surgical
excision of the retroperitoneal mass (June, 2010), she
developed progressive dyspnea and a pulmonary function
test revealed a mixed respiratory disorder. A thoracic CT
scan showed patchy areas of ground-glass opacity.
Thromboembolism was excluded. She was treated with
high doses of prednisolone, colchicines, cyclosporine
200mg/day, with no response. Extensive mucosal ero-
sions were still present, the tumor markers kept on rising
and she presented a severe pulmonary restriction. We
decided to initiate Tocilizumab EOW associated with
moderate dose of prednisone.
Results
After 5 months of Tocilizumab use, the oral lesions
were considerably better, but there were only a subtle
increase of forced vital capacity and little (if some) pul-
monary clinical response. A PET scan failed to show
new tumor lesions. Although most patients with the
benign type of CD have shown remission of PNP upon
excision of the tumor, our patient showed severe pul-
monary involvement despite of IL6 blockage treatment.
Conclusion
Although the association of Behçet’s disease and pemphi-
gus is very intriguing, CD should always be investigated in
a young patient with PNP. Localized hyaline-vascular CD
is generally benign, fully responding to surgery. However,
the presence of PNP with pulmonary involvement carries
a poor prognosis.
Disclosure
Ana Beatriz Vargas: None; Beatriz M. Trope: None;
Blanca E. R. G. Bica: None.
Published: 13 July 2012
doi:10.1186/1546-0096-10-S1-A95
Cite this article as: Vargas et al.: Tocilizumab for refractory Castleman’s
disease with paraneoplastic pemphigus and Behçet’s disease. Pediatric
Rheumatology 2012 10(Suppl 1):A95.Hospital Universitário Clementino Fraga Filho - Universidade Federal do Rio
de Janeiro, Rio de Janeiro, Brazil
Vargas et al. Pediatric Rheumatology 2012, 10(Suppl 1):A95
http://www.ped-rheum.com/content/10/S1/A95
© 2012 Vargas et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
